CorrespondenceBevacizumab vs Ranibizumab for Age-Related Macular Degeneration: Early Results of a Prospective Double-Masked, Randomized Clinical Trial
Reference (1)
- et al.
Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial
Am J Ophthalmol
(2009)
Cited by (5)
Angiogenesis inhibition by the maleimide-based small molecule GNX-686
2012, Microvascular ResearchCitation Excerpt :Pathologic ocular neovascularization can be treated using various treatment modalities e.g. photodynamic therapy (American Academy of Ophthalmology, 2000), laser photocoagulation (Sasai et al., 1997), or surgical removal (Kaplan, 1996). Over the past few years, several drugs have been introduced to the market for intravitreal injections for ocular conditions involving angiogenesis, including pegaptanib sodium/Macugen® (Apte et al., 2007), ranibizumab/Lucentis® (Donahue et al., 2010; Fayers, 2011; Schmucker et al., 2010), and bevacizumab/Avastin® (Schmucker et al., 2010). All of these agents neutralize VEGF preventing the induction of endothelial proliferation and angiogenesis.
LiGluR restores visual responses in rodent models of inherited blindness
2011, Molecular TherapyCitation Excerpt :We found the pupillary light response to persist for 1–2 weeks after MAG injection. For longer treatments, MAG would have to be supplied repeatedly or via slow release, as for intravitreally injected agents used to treat retinal neovascularization.43 Second, it would be beneficial if RGCs that are rendered light-sensitive in order to take over for missing photoreceptor cells were to respond to visible light.
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration
2014, Cochrane Database of Systematic ReviewsTargeting non-malignant disorders with tyrosine kinase inhibitors
2010, Nature Reviews Drug Discovery